within Pharmacolibrary.Drugs.ATC.N;

model N02AX01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.06,
    Cl             = 4.1666666666666665e-05,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0036,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 600,            
    Vdp             = 0.0092,
    k12             = 8.1,
    k21             = 8.1
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N02AX01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tilidine is a synthetic opioid analgesic used for the relief of moderate to severe pain. It is administered as a racemate but acts through its active metabolite nortilidine. Tilidine is still approved and used in some European countries, such as Germany, but is not commonly available or approved in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single oral dose administration.</p><h4>References</h4><ol><li><p>Seiler, KU, et al., &amp; Heintz, B (2001). Pharmacokinetics of tilidine in terminal renal failure. <i>Journal of clinical pharmacology</i> 41(1) 79–84. DOI:<a href=&quot;https://doi.org/10.1177/00912700122009863&quot;>10.1177/00912700122009863</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11144998/&quot;>https://pubmed.ncbi.nlm.nih.gov/11144998</a></p></li><li><p>Brennscheidt, U, et al., &amp; Thomann, P (2000). Pharmacokinetics of nortilidine and naloxone after administration of tilidine/naloxone solution or tilidine/naloxone sustained release tablets. <i>Arzneimittel-Forschung</i> 50(11) 1015–1022. DOI:<a href=&quot;https://doi.org/10.1055/s-0031-1300326&quot;>10.1055/s-0031-1300326</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11148857/&quot;>https://pubmed.ncbi.nlm.nih.gov/11148857</a></p></li><li><p>Brennscheidt, U, et al., &amp; Seiler, KU (2007). Pharmacokinetics of tilidine and naloxone in patients with severe hepatic impairment. <i>Arzneimittel-Forschung</i> 57(2) 106–111. DOI:<a href=&quot;https://doi.org/10.1055/s-0031-1296591&quot;>10.1055/s-0031-1296591</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17396621/&quot;>https://pubmed.ncbi.nlm.nih.gov/17396621</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N02AX01;
